A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long-Term Safety, Tolerability, Pharmocokinetics and Effects of ALK-001 on the Progression of Stargardt Disease

This Study is
No Longer Enrolling

Description

The TEASE studies (Tolerability and Effects of ALK-001 in Stargardt Disease) are a series of clinical trials evaluating an investigational drug called ALK-001 in people who have Stargardt Disease. There are no FDA-approved treatments to slow the progression of Stargardt Disease. Research studies are conducted to determine if an investigational drug is safe and effective.

Details
Age

Child to Adult

Eligibility

Participants in this study must be at least 8 years old and diagnosed with Stargardt Disease, as confirmed by genetic testing, and must meet all other eligibility criteria.

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 19-1103

More information available at ClinicalTrials.gov: NCT02402660

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers